Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Natalizumab Stories

2011-10-05 12:54:24

Taking the new generation anti-inflammatory drug natalizumab for two years lowers the number of remitting multiple sclerosis patients who experience relapses and progression of disability. This is the main finding of a systematic review published in the latest edition of The Cochrane Library. Multiple sclerosis (MS) is a disease that damages a person's nervous system. The symptoms vary considerably from person to person, but many have a form of the disease in which they feel healthy for a...

2011-09-21 12:15:00

Biopharma intelligence provider will also moderate live panel on funding biopharma innovation at Prix Galien USA on September 27 in NYC. Norwood, MA (PRWEB) September 21, 2011 Over the following week, BioPharm Insight Global Editor Kimberly Ha will host two important and educational expert panels â“ one live, one online â“ focused on funding biopharma innovation and the Multiple Sclerosis drug development landscape, respectively. September 27, 2011...

2011-08-16 06:10:00

ATLANTA, Aug. 16, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML). This proof-of-concept trial will be conducted in multiple sclerosis (MS)...

548664ef58ca68c620a46c44f91b0cc3
2011-07-21 14:20:00

According to a new study, drugs used in the hope of slowing multiple sclerosis progression may come at a high cost for some patients who choose to use them. The medications in question are considered disease-modifying drugs (DMDs) that have been available since the 1990s to treat multiple sclerosis. The drugs include beta interferons, glatiramer and natalizumab.  They are given by injection or infusion and can prevent MS symptom flare-ups and delay long-term disability from the...

2011-06-28 00:00:33

This report provides perspective on the MS landscape in light of Merck Serono's decision to discontinue development and marketing of cladribine for MS. Scottsdale, AZ (PRWEB) June 27, 2011 MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled "Thought Leader Insight & Analysis: Multiple Sclerosis," designed to provide critical strategic insight for pharma and biotech companies with a stake in the...

2011-05-27 09:00:00

LONDON and BRUSSELS, May 27, 2011 /PRNewswire/ -- UCB today announced data which showed that the addition of Cimzia® (certolizumab pegol) to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients. Consistent efficacy was observed across patients taking certolizumab pegol whether they had previously received TNF inhibitors or not and whether they received certolizumab pegol monotherapy* or with...

2011-05-16 09:00:00

BRUSSELS, May 16, 2011 /PRNewswire/ -- The ACR hybrid score, a new measure of response to RA treatment recently developed by the American College of Rheumatology, demonstrated improved sensitivity compared to traditional ACR responses, according to recently published results in Arthritis Care & Research. Traditional ACR20/50/70 and DAS28 scores were compared to the ACR hybrid score in a post-hoc analysis of the RAPID 1 study, the first clinical trial data to be analyzed using the ACR...

2011-05-10 09:00:00

BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced results from a post hoc analysis of the RAPID 2 study, published in the Annals of Rheumatic Diseases, which showed Cimzia®, the only approved PEGylated anti-TNF, plus methotrexate (MTX) provided rapid relief from a broad range of symptoms associated with the burden of moderate to severe active rheumatoid arthritis (RA). Those adult patients treated with Cimzia® that achieved early responses were found...

2011-05-10 09:00:00

BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis (RA) patients treated with Cimzia® (certolizumab pegol), the only approved PEGylated anti-TNF, together with methotrexate (MTX), achieved a rapid response associated with improved long-term outcomes one year after treatment began. "These results are consistent...

2011-04-11 07:30:00

ALISO VIEJO, Calif., April 11, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of William (Bill) Sibold to the position of senior vice president and chief commercial officer. In this newly created role, Mr. Sibold will be responsible for leading all of the company's commercial activities. "Bill has an outstanding track record of success in biopharmaceutical sales and marketing," said Keith A. Katkin, president and CEO of Avanir. "I am...